Lyn­parza im­proves sur­vival rate in prostate can­cer, giv­ing As­traZeneca and Mer­ck an­oth­er win on PARP front

As­traZeneca and its part­ners at Mer­ck can tack on an­oth­er key clin­i­cal win for their block­buster can­cer drug star Lyn­parza. Fol­low­ing up on their suc­cess in gain­ing an im­por­tant im­prove­ment on pro­gres­sion free sur­vival for a seg­ment of ad­vanced prostate can­cer pa­tients, the phar­ma gi­ants say they now have ev­i­dence the drug al­so spurs longer over­all sur­vival.

Cur­rent­ly un­der pri­or­i­ty re­view with an ac­cel­er­at­ed OK ex­pect­ed soon, the As­traZeneca team re­port­ed their score on OS for pa­tients with metasta­t­ic cas­tra­tion-re­sis­tant prostate can­cer who have a ho­mol­o­gous re­com­bi­na­tion re­pair gene mu­ta­tion and have pro­gressed on pri­or treat­ment with new hor­mon­al agent drugs — like Xtan­di (en­za­lu­tamide) and Zyti­ga (abi­raterone).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER